The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Combination Chemotherapy in the Treatment of Advanced Hodgkin's Disease
Abstract
Forty-three patients with advanced, primarily untreated Hodgkin's disease were treated with a combination of vincristine sulfate, nitrogen mustard (or cyclophosphamide), procarbazine hydrochloride, and prednisone, given in cyclical fashion for 6 months. The limiting toxicity was primarily bone marrow suppression and, although occasionally severe, was generally tolerable. Other toxicity such as alopecia and neurotoxicity were troublesome but reversible. The response rate was superior to that previously reported with the use of single drugs with 35 of 43, or 81% of the patients achieving a complete remission, defined as the complete disappearance of all tumor and return to normal performance status. The duration of these responses after all therapy was discontinued was gratifyingly long, with a median of not less than 29 and not more than 42 months. Seventeen of 35 patients continue free of their disease, and 28 of these 35 are still alive. The median survival of the responding group is greater than 42 months, and life table analysis of the results indicates that of those complete responders at risk for 4 years, 77% remain alive and 47% are continuously free of their disease. The surviving fraction of the entire group at risk 4 years is 63%. It appears that combinations of effective drugs that act by different mechanisms and manifest different toxicities can be used effectively to increase the response rate and probably the survival of patients with sensitive tumors such as Hodgkin's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Skipper, H. E., Schabel, F. M., & Wilcox, W. S. (1964) · PubMed · Cited by 767
FREI, E., KARON, M., LEVIN, R. H., FREIREICH, E. J., TAYLOR, R. J., HANANIAN, J., SELAWRY, O., HOLLAND, J. F., HOOGSTRATEN, B., WOLMAN, I. J., et al. (1965) · Blood · doi:10.1182/blood.v26.5.642.642 · Cited by 325
The Transmission of Leukemia of Mice with a Single Cell
Fürth, J., Kahn, M. C., & Breedis, C. (1937) · American Journal of Cancer · doi:10.1158/ajc.1937.276 · Cited by 271
IMPAIRED DELAYED HYPERSENSITIVITY IN PATIENTS WITH LEPROMATOUS LEPROSY
Waldorf, D. S., Sheagren, J., Trautman, J., & Block, J. (1966) · The Lancet · doi:10.1016/s0140-6736(66)90366-7 · Cited by 132
METHYL-HYDRAZINE IN TREATMENT OF HODGKIN'S DISEASE AND VARIOUS FORMS OF HÆMATOSARCOMA AND LEUKÆMIA
Mathé, G., Schweisguth, O., Schneider, M., Amiel, J. L., Bérumen, L., Brulé, G., Cattan, A. R., & Schwarzenberg, L. (1963) · The Lancet · doi:10.1016/s0140-6736(63)92854-x · Cited by 88
Intensive Combination Chemotherapy and X-Irradiation in Hodgkin's Disease
DeVita, V. T., DeVita-Raeburn, E., & Moxley, J. H. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0470 · Cited by 80
Self-citationHe, S., Fm, S., & Wilcox, W. S. (1965) · PubMed · Cited by 72
Drug Synergism in Antineoplastic Chemotherapy
Venditti, J. M., & GOLDIN, A. S. (1964) · Elsevier eBooks · doi:10.1016/b978-1-4831-9929-0.50013-9 · Cited by 67
High-Dose Corticoid Therapy in Hodgkin's Disease and other Lymphomas
Hall, T. C., CHOI, O. S., ABADI, A., & KRANT, M. J. (1967) · Annals of Internal Medicine · doi:10.7326/0003-4819-66-6-1144 · Cited by 48
Todd, I. D. H. (1965) · BMJ · doi:10.1136/bmj.1.5435.628 · Cited by 42
Cited by
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
EINHORN, L. H., & DONOHUE, J. (1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-3-293 · Cited by 1,545
EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary
Sant, M., Allemani, C., Santaquilani, M., Knijn, A., Marchesi, F., & Capocaccia, R. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.11.018 · Cited by 1,021
Assessment of the Evolution of Cancer Treatment Therapies
Arruebo, M., Vilaboa, N., Sáez-Gutierrez, B., Lambea, J., Tres, A., Valladares, M., & González-Fernández, Á. (2011) · Cancers · doi:10.3390/cancers3033279 · Cited by 931
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Falzone, L., Salomone, S., & Libra, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01300 · Cited by 908
Metadata
- Authors
- DEVITA, V. T., SERPICK, A. A., & CARBONE, P. P.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1970-12-01
- Volume
- 73
- Issue
- 6
- Pages
- 881-895
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2092015388
- Cited by
- 1,436
- References
- 12
- FWCI
- 69.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination Chemotherapy in the Treatment of Advanced Hodgkin's Disease. https://app.cochat.ai/papers/10.7326/0003-4819-73-6-881
- The paper
- DEVITA, V. T., SERPICK, A. A., & CARBONE, P. P. (1970). Combination Chemotherapy in the Treatment of Advanced Hodgkin's Disease. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-73-6-881
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
